肿瘤(癌症)患者之家
首页
癌症知识
肿瘤中医药治疗
肿瘤药膳
肿瘤治疗技术
前沿资讯
登录/注册
VIP特权

文章目录

为癌症免疫治疗设计自然杀伤细胞的输送技术

Delivery technologies to engineer natural killer cells for cancer immunotherapy 

原文发布日期:2021-04-22 

英文摘要:

摘要翻译: 

原文链接:

文章:

为癌症免疫治疗设计自然杀伤细胞的输送技术

Delivery technologies to engineer natural killer cells for cancer immunotherapy 

原文发布日期:2021-04-22 

英文摘要:

In recent years, immune cell-based cancer therapeutics have been utilized broadly in the clinic. Through advances in cellular engineering, chimeric antigen receptor (CAR) T-cell therapies have demonstrated substantial success in treating hematological tumors and have become the most prominent cell-based therapy with three commercialized products in the market. However, T-cell-based immunotherapies have certain limitations, including a restriction to autologous cell sources to avoid severe side-effects caused by human leukocyte antigen (HLA) mismatch. This necessity for personalized treatment inevitably results in tremendous manufacturing and time costs, reducing accessibility for many patients. As an alternative strategy, natural killer (NK) cells have emerged as potential candidates for improved cell-based immunotherapies. NK cells are capable of killing cancer cells directly without requiring HLA matching. Furthermore, NK cell-based therapies can use various allogeneic cell sources, allowing for the possibility of “off-the-shelf” immunotherapies with reduced side-effects and shortened manufacturing times. Here we provide an overview of the use of NK cells in cancer immunotherapy, their current status in clinical trials, as well as the design and implementation of delivery technologies—including viral, non-viral, and nanoparticle-based approaches—for engineering NK cell-based immunotherapies. 

摘要翻译: 

近年来,基于免疫细胞的癌症治疗手段已在临床得到广泛应用。随着细胞工程技术的进步,嵌合抗原受体(CAR)T细胞疗法在治疗血液肿瘤方面取得显著成效,已成为最突出的细胞治疗方法,目前已有三种商业化产品上市。然而,基于T细胞的免疫疗法存在一定局限性,包括必须使用自体细胞来源以避免人类白细胞抗原(HLA)不匹配引发的严重副作用。这种个性化治疗的需求不可避免地导致巨大的生产成本和时间成本,降低了多数患者的可及性。作为一种替代策略,自然杀伤(NK)细胞已成为改进细胞免疫疗法的潜在候选者。NK细胞能够直接杀伤癌细胞且无需HLA配型。此外,基于NK细胞的疗法可采用多种异体细胞来源,为实现"即用型"免疫疗法提供了可能,这种疗法不仅副作用更小,还能缩短生产时间。本文概述了NK细胞在癌症免疫治疗中的应用、临床试验现状,以及用于开发NK细胞免疫疗法的递送技术(包括病毒载体、非病毒载体和纳米颗粒方法)的设计与实施。

原文链接:

Delivery technologies to engineer natural killer cells for cancer immunotherapy 

相关文章

文章:肿瘤抗原优先来源于黑色素瘤和非小细胞肺癌中未突变的基因组序列
文章:年龄相关的烟酰胺腺嘌呤二核苷酸下降驱动CAR-T细胞衰竭
文章:MCSP+转移创始细胞在人类黑色素瘤转移定植早期激活免疫抑制
文章:脂质纳米颗粒递送合成抗原使实体瘤对car介导的细胞毒性敏感
文章:食管癌新辅助治疗中的进化和免疫微环境动力学
文章:CHD1缺失重编程srebp2驱动的胆固醇合成,在spop突变的前列腺肿瘤中促进雄激素响应性生长和去势抵抗
文章:对TIL细胞治疗无反应的转移性非小细胞肺癌患者的T细胞和新抗原保留受损的时间序列分析
文章:策展的癌细胞图谱提供了单细胞分辨率的肿瘤的全面表征
文章:以人群为基础的胶质瘤分子景观分析在青少年和年轻人揭示胶质瘤形成的见解
文章:肿瘤细胞上的PILRα与T细胞表面蛋白CD99相互作用抑制抗肿瘤免疫

……